Efficacy of Septilin Drops in Respiratory Disorders
Phase 2
- Conditions
- Health Condition 1: null- Patients with URTI symptoms like cough, cold, fever and devoid of serious illness requiring conventional treatment.
- Registration Number
- CTRI/2016/04/006864
- Lead Sponsor
- The Himalaya Drug Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
above age group patients having URTI signs and symptoms
Exclusion Criteria
•Those with serious Cardiovascular, Cerebro vascular, Respiratory, Liver or Renal disease or any other disorder.
•Children with congenital abnormality.
•Subjects with a strong history of food or drug allergy of any kind.
•During course of treatment if the subject develops any acute illness requiring acute management, such patients will be excluded out of the study and continued with conventional treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relieving of symptomsTimepoint: Assessment will be done on 7th , 15th , 30th,and 45th day during study
- Secondary Outcome Measures
Name Time Method ImmunomodulationTimepoint: 45 days